Nagayama A[au] - Search Results

Year	Number of Results
1964	1
1968	2
1969	1
1970	1
1973	1
1974	1
1976	1
1978	1
1979	1
1981	1
1983	3
1985	2
1986	2
1987	1
1988	4
1991	2
1992	2
1995	5
1996	2
1997	4
1998	2
1999	3
2000	1
2001	1
2002	2
2003	4
2004	9
2005	3
2006	1
2007	2
2008	4
2009	1
2010	4
2011	1
2012	2
2013	1
2014	6
2015	4
2016	1
2017	4
2018	5
2019	5
2020	7
2021	9
2022	4

1

Novel antibody-drug conjugates for triple negative breast cancer.

Nagayama A, Vidula N, Ellisen L, Bardia A. Nagayama A, et al. Ther Adv Med Oncol. 2020 May 11;12:1758835920915980. doi: 10.1177/1758835920915980. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32426047 Free PMC article. Review.

2

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.

Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y. Yokoe T, et al. Among authors: nagayama a. Oncologist. 2019 Jun;24(6):e347-e357. doi: 10.1634/theoncologist.2018-0140. Epub 2018 Oct 17. Oncologist. 2019. PMID: 30333194 Free PMC article.

3

Response.

Nagayama A, Hayashida T, Jinno H, Takahashi M, Kitagawa Y. Nagayama A, et al. J Natl Cancer Inst. 2015 Mar 3;107(4):djv039. doi: 10.1093/jnci/djv039. Print 2015 Apr. J Natl Cancer Inst. 2015. PMID: 25739418 No abstract available.

4

Quinacrine is not a vital fluorescent probe for vesicular ATP storage.

Hasuzawa N, Moriyama S, Wang L, Nagayama A, Ashida K, Moriyama Y, Nomura M. Hasuzawa N, et al. Among authors: nagayama a. Purinergic Signal. 2021 Dec;17(4):725-735. doi: 10.1007/s11302-021-09820-8. Epub 2021 Oct 28. Purinergic Signal. 2021. PMID: 34713379 Free PMC article.

5

Symbiont-mediated insecticide resistance.

Kikuchi Y, Hayatsu M, Hosokawa T, Nagayama A, Tago K, Fukatsu T. Kikuchi Y, et al. Among authors: nagayama a. Proc Natl Acad Sci U S A. 2012 May 29;109(22):8618-22. doi: 10.1073/pnas.1200231109. Epub 2012 Apr 23. Proc Natl Acad Sci U S A. 2012. PMID: 22529384 Free PMC article.

6

A transposon screen identifies enhancement of NF-κB pathway as a mechanism of resistance to eribulin.

Teng X, Hayashida T, Murata T, Nagayama A, Seki T, Takahashi M, Kitagawa Y. Teng X, et al. Among authors: nagayama a. Breast Cancer. 2021 Jul;28(4):884-895. doi: 10.1007/s12282-021-01224-1. Epub 2021 Feb 22. Breast Cancer. 2021. PMID: 33616862

7

Thyroid-related ophthalmopathy development in concurrence with growth hormone administration.

Iwata S, Tsumura K, Ashida K, Tokubuchi I, Demiya M, Kitamura M, Ohshima H, Yano M, Nagayama A, Yasuda J, Tsuruta M, Motomura S, Yoshida S, Nomura M. Iwata S, et al. Among authors: nagayama a. BMC Endocr Disord. 2021 Aug 19;21(1):168. doi: 10.1186/s12902-021-00834-2. BMC Endocr Disord. 2021. PMID: 34412613 Free PMC article.

8

Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Nagayama A, Ellisen LW, Chabner B, Bardia A. Nagayama A, et al. Target Oncol. 2017 Dec;12(6):719-739. doi: 10.1007/s11523-017-0535-0. Target Oncol. 2017. PMID: 29116596 Review.

9

Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.

Nagayama A, Vidula N, Bardia A. Nagayama A, et al. Oncology (Williston Park). 2021 May 13;35(5):249-254. doi: 10.46883/ONC.2021.3505.0249. Oncology (Williston Park). 2021. PMID: 33983696 Review.

10

The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer.

Nakashoji A, Hayashida T, Yokoe T, Maeda H, Toyota T, Kikuchi M, Watanuki R, Nagayama A, Seki T, Takahashi M, Abe T, Kitagawa Y. Nakashoji A, et al. Among authors: nagayama a. Cancer Treat Rev. 2018 Jan;62:9-17. doi: 10.1016/j.ctrv.2017.10.009. Epub 2017 Oct 31. Cancer Treat Rev. 2018. PMID: 29127857 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results